Eyegate Pharmaceuticals (NASDAQ: EYEG) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Eyegate Pharmaceuticals to related companies based on the strength of its profitability, risk, dividends, valuation, earnings, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by company insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for Eyegate Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eyegate Pharmaceuticals Competitors||847||3782||6814||185||2.54|
Eyegate Pharmaceuticals presently has a consensus target price of $7.33, suggesting a potential upside of 564.97%. As a group, “Pharmaceuticals” companies have a potential upside of 23.06%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than its competitors.
Valuation and Earnings
This table compares Eyegate Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eyegate Pharmaceuticals||$767,481.00||-$13.31 million||-0.85|
|Eyegate Pharmaceuticals Competitors||$8.08 billion||$2.63 billion||-0.02|
Eyegate Pharmaceuticals’ competitors have higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Eyegate Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eyegate Pharmaceuticals Competitors||-2,859.53%||-67.82%||-9.13%|
Volatility & Risk
Eyegate Pharmaceuticals has a beta of 3.27, meaning that its stock price is 227% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals’ competitors have a beta of 0.95, meaning that their average stock price is 5% less volatile than the S&P 500.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
What are top analysts saying about Eyegate Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eyegate Pharmaceuticals Inc. and related companies.